GH Research GHRS 深 沪
已收盘 11-13 16:00:00 美东时间
19.10
+0.610
+3.30%
华盛通- 最 高19.81
- 今 开18.84
- 成交量 56.02万股
- 最 低 18.00
- 昨 收 18.49
- 总市值 13.11亿
- 52周最高 31.439
- 市盈率 静 --
- 换手率 0.82%
- 52周最低 12.04
- 委 比 -6.34%
- 总股本 6864.23万
- 历史最高 31.439
- 量 比 2.60
- 振 幅 9.79%
- 历史最低 5.05
- 每 手 1
- 风险率 5.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GH Research Q3 EPS $(0.18) Beats $(0.32) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 21.74 percent increase over losses of $(0.23) per share from the same period last year.
11-13 21:05
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
GH Research PLC reported positive updates on its GH001 program for treating depression, including FDA feedback on its pivotal trial design and plans to initiate trials in 2027. The company also announced the appointment of Dr. Vanina Popova as Chief Development Officer. Financially, the company ended September 2026 with $350.6 million in cash, showing reduced R&D and G&A expenses compared to the prior year.
11-13 13:00
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
GH Research PLC has appointed Dr. Vanina Popova as Chief Development Officer to lead the clinical development of GH001 for treatment-resistant depression (TRD) and postpartum depression (PPD). Dr. Popova brings over 20 years of experience in global pharmaceutical R&D, including leadership in the Spravato® (esketamine) program, where she led pivotal Phase 3 trials for TRD. Her expertise will guide GH001's pivotal programs, aiming to address signif...
11-13 12:55
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Needham Maintains Buy on GH Research, Raises Price Target to $39
Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $32 to $39.
08-07 02:19
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 53.33 percent decrease over losses of $(0.15) per share from the same period last year.
08-06 19:19
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
GH Research PLC reported financial results for Q2 2026, with cash, cash equivalents, and marketable securities totaling $362.7 million. The company achieved alignment with the FDA on CMC and device plans for Phase 3, successfully completed Phase 1 trials GH001-HV-106 and GH001-HV-109, and strengthened its US and EU mebufotenin patents. Phase 2a results for postpartum depression were published in The Journal of Clinical Psychiatry. R&D expenses ro...
08-06 11:00
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44
Wells Fargo analyst Benjamin Burnett initiates coverage on GH Research (NASDAQ:GHRS) with a Overweight rating and announces Price Target of $44.
07-27 20:49
巨头并购、政策开闸、数据井喷……迷幻药变天前夜，市场收到一记38亿美元的多头信号
上周四，礼来公司(LLY.US)宣布将以高达38亿美元的价格收购临床阶段迷幻药物制造商AtaiBeckley(ATAI.US)。这一动作标志着，大型制药企业正日...
07-20 08:48
